X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing enables RenovoRx to progress its primary program, the pivotal TIGeR-PaC study, evaluating RenovoGem (gemcitabine) in a clinical trial for locally advanced pancreatic cancer.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoGem
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newbridge Securities Corporation
Deal Size: $11.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 15, 2024
Details:
The financing enables RenovoRx to progress its primary program, the pivotal TIGeR-PaC study, evaluating RenovoGem (gemcitabine) in a clinical trial for locally advanced pancreatic cancer.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoGem
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newbridge Securities Corporation
Deal Size: $11.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 08, 2024
Details:
The net proceeds will focus on the development of RenovoGem (gemcitabine), a novel oncology drug-device combination product for the treatment of locally advanced pancreatic cancer.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoGem
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Paulson Investment Company
Deal Size: $6.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 29, 2024
Details:
The collaboration aims to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.
Lead Product(s): Oncolytic Virus Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Imugene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 20, 2023
Details:
RenovoGem™ (gemcitabine), FDA-approved chemotherapy, delivered via the company’s proprietary delivery system, utilizes pressure-mediated delivery of drug across the arterial wall to bathe tumor tissue in chemotherapy via RenovoTAMP®.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoGem
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
RenovoGem™ (gemcitabine), FDA-approved chemotherapy, delivered via utilizing pressure-mediated delivery of drug across the arterial wall to bathe tumor tissue in chemotherapy via RenovoTAMP®, it is being investigated for pancreatic cancer.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoGem
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Details:
RenovoGem™ (gemcitabine), FDA-approved chemotherapy, delivered via the company’s proprietary delivery system, utilizes pressure-mediated delivery of drug across the arterial wall to bathe tumor tissue in chemotherapy via RenovoTAMP®.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoGem
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
Details:
RenovoGem™ (gemcitabine), FDA-approved chemotherapy, delivered via the company’s proprietary delivery system, utilizes pressure-mediated delivery of drug across the arterial wall to bathe tumor tissue in chemotherapy via RenovoTAMP®.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoGem
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
RenovoGem, is a combination of gemcitabine and its patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC).
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoCath
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
RenovoGem, is a combination of gemcitabine and our patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC).
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoGem
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
